Condition: Respiratory Syncytial Virus (RSV) · Sponsor: MAXVAX Biotechnology Limited Liability Company
This study will evaluate the efficacy of the Recombinant RSV vaccine(CHO cell) vaccine in preventing lower respiratory tract diseases(LRTD) caused by RSV in adults≥ 60 years of following a single dose of the RSV vaccine(CHO cell) vaccine .This study will also assess if the vaccine is safe and induces an immune response.
This description comes directly from the study's public registry record.
LiangHao Zhang · +86 18971498772 · lianghao.zhang@maxvax.cn
Always discuss trial participation with your own doctor first.
| Guangdong Provincial Center for Disease Control and Prevention | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Hebei Provincial Center for Disease Control and Prevention | Shijiazhuang, Hebei, China | Active Not Recruiting |
| Henan Center for Disease Control and Prevention | Zhengzhou, Henan, China | Recruiting |
| Hubei Provincial Center for Disease Control and Prevention | Wuhan, Hubei, China | Recruiting |
| Hunan Provincial Center for Disease Control and Prevention | Changsha, Hunan, China | Recruiting |
| Shaanxi Provincial Center for Disease Control and Prevention | Xi'an, Shaanxi, China | Recruiting |
| Shandong Province Centers for Disease Control and Prevention | Jinan, Shandong, China | Active Not Recruiting |
| Sichuan Center for Disease Control and Prevention | Chengdu, Sichuan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07272434